BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
CLSA maintains sell on Aurobindo Pharma
CLSA has maintained sell on Aurobindo Pharma for target price of Rs 630. CLSA says Aurobindo should trade at discount to peers and see several challenges & muted growth. It adds that EBITDA margin is unlikely to improve and balance sheet is weaker than peers. CLSA expects slow earnings growth phase and valuations are cheap only optically.